Suppr超能文献

从内部代谢活性定义生物制造过程中的黄金批次,以检测可能影响产品质量的过程变化。

Defining Golden Batches in Biomanufacturing Processes From Internal Metabolic Activity to Detect Process Changes That May Affect Product Quality.

作者信息

Bush Xin, Fratz-Berilla Erica J, Kohnhorst Casey L, King Roberta, Agarabi Cyrus, Powers David N, Trunfio Nicholas

机构信息

U.S. Food and Drug Administration, Center for Drug Evaluation and Research, Office of Pharmaceutical Quality, Office of Pharmaceutical Quality Research, Division Pharmaceutical Quality Research VI, Silver Spring, Maryland, USA.

U.S. Food and Drug Administration, Center for Drug Evaluation and Research, Office of Pharmaceutical Quality, Office of Pharmaceutical Quality Research, Division Pharmaceutical Quality Research III, Silver Spring, Maryland, USA.

出版信息

Biotechnol Bioeng. 2025 Feb;122(2):298-305. doi: 10.1002/bit.28873. Epub 2024 Oct 27.

Abstract

Cellular metabolism plays a role in the observed variability of a drug substance's Critical Quality Attributes (CQAs) made by biomanufacturing processes. Therefore, here we describe a new approach for monitoring biomanufacturing processes that measures a set of metabolic reaction rates (named Critical Metabolic Parameters (CMP) in addition to the macroscopic process conditions currently being used as Critical Process Parameters (CPP) for biomanufacturing. Constraint-based systems biology models like Flux Balance Analysis (FBA) are used to estimate metabolic reaction rates, and metabolic rates are used as inputs for multivariate Batch Evolution Models (BEM). Metabolic activity was reproducible among batches and could be monitored to detect a deliberately induced macroscopic process shift (i.e., temperature change). The CMP approach has the potential to enable "golden batches" in biomanufacturing processes to be defined from the internal metabolic activity and to aid in detecting process changes that may impact the quality of the product. Overall, the data suggested that monitoring of metabolic activity has promise for biomanufacturing process control.

摘要

细胞代谢在生物制造过程中药物关键质量属性(CQA)所观察到的变异性中发挥作用。因此,我们在此描述一种监测生物制造过程的新方法,该方法除了测量目前用作生物制造关键工艺参数(CPP)的宏观工艺条件外,还测量一组代谢反应速率(称为关键代谢参数(CMP))。基于约束的系统生物学模型(如通量平衡分析(FBA))用于估计代谢反应速率,代谢速率用作多变量批次演化模型(BEM)的输入。代谢活性在批次间具有可重复性,并且可以进行监测以检测故意诱导的宏观工艺变化(即温度变化)。CMP方法有可能根据内部代谢活性定义生物制造过程中的“黄金批次”,并有助于检测可能影响产品质量的工艺变化。总体而言,数据表明监测代谢活性在生物制造过程控制方面具有前景。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0267/11718427/73136b8ba008/BIT-122-298-g005.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验